Market Research Report
North America Immunosuppressant Drugs Market Forecast 2019-2028
|Published by||Inkwood Research||Product code||939708|
|Published||Content info||105 Pages
Delivery time: 2-3 business days
|North America Immunosuppressant Drugs Market Forecast 2019-2028|
|Published: June 1, 2020||Content info: 105 Pages||
The North America immunosuppressant drugs market is projected to record growth at a CAGR of 3.19% during the forecast period, 2019-2028. The surge in demand for organ transplantation, as a result of increasing organ failure incidences, is the influential factor in stimulating market growth.
The North America immunosuppressant drugs market growth analysis involves market evaluation of Canada and the United States. Canada has the presence of major pharmaceutical companies. The pharmaceutical industry of the country comprises of an ecosystem of local and multinational companies. A large part of the Canadian population is affected by autoimmune diseases. Sjogren's syndrome is one such autoimmune disorder that is prevalent in Canada. Immunosuppressant drugs are an instrumental part of treatment for such autoimmune disorders. Over the years, there has been an increase in the NDD (NDD, or neurological determination of death) donors and a decrease in the DCD (donation after cardio-circulatory death) donors. DCD was practiced in the country since 2006. There have also been significant variations in the type of organs being transplanted. Such factors are attributed to the growth of the market under study.
Some of the eminent companies progressing in the market are Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Astellas Pharma Inc, AbbVie Inc, Cipla Ltd, etc.
Our report offerings include:
Explore key findings of the overall market